Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 11, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 875,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,249.94 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.07% of total voting rights).
- Shares in Issue: 5,228,394,545 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 875,000 shares purchased on September 11, 2008. Consequently, the number of shares held in Treasury increased to 474,194,158.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a statutory notification of a share transaction and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,228,394,545) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.07%).
- Note that this filing does not contain operational or financial performance data for the period.